Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

979 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R. Wheler JJ, et al. Among authors: kurzrock r. Mol Cancer Ther. 2013 Oct;12(10):2167-75. doi: 10.1158/1535-7163.MCT-12-1208. Epub 2013 Aug 20. Mol Cancer Ther. 2013. PMID: 23963360 Free PMC article. Clinical Trial.
Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Schwaederle M, et al. Among authors: kurzrock r. Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5. Oncologist. 2014. PMID: 24797821 Free PMC article.
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Wheler JJ, Moulder SL, Naing A, Janku F, Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Wheler JJ, et al. Among authors: kurzrock r. Oncotarget. 2014 May 30;5(10):3029-38. doi: 10.18632/oncotarget.1799. Oncotarget. 2014. PMID: 24912489 Free PMC article. Clinical Trial.
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Ganesan P, Moulder S, Lee JJ, Janku F, Valero V, Zinner RG, Naing A, Fu S, Tsimberidou AM, Hong D, Stephen B, Stephens P, Yelensky R, Meric-Bernstam F, Kurzrock R, Wheler JJ. Ganesan P, et al. Among authors: kurzrock r. Mol Cancer Ther. 2014 Dec;13(12):3175-84. doi: 10.1158/1535-7163.MCT-14-0358. Epub 2014 Sep 24. Mol Cancer Ther. 2014. PMID: 25253784 Free PMC article.
Cyclin alterations in diverse cancers: Outcome and co-amplification network.
Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R. Schwaederlé M, et al. Among authors: kurzrock r. Oncotarget. 2015 Feb 20;6(5):3033-42. doi: 10.18632/oncotarget.2848. Oncotarget. 2015. PMID: 25596748 Free PMC article.
979 results